Pfizer's New Biosimilar Is Off and Running

Pfizer's New Biosimilar Is Off and Running


Remicade, late last year, and fourth-quarter earnings reports from the two companies provide us with insight into Inflectra's market potential. Can Inflectra become a top seller? Read on to find out how big the market could be for this new biosimilar.



from Biotech News